<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2011-6-1-35-38</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Thyroid function in children and adolescents after combined therapy of Hodgkin disease</article-title><trans-title-group xml:lang="ru"><trans-title>Функция щитовидной железы после комбинированной терапии болезни Ходжкина у детей и подростков</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Feoktistov</surname><given-names>R. I.</given-names></name><name xml:lang="ru"><surname>Феоктистов</surname><given-names>Р. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>feoktistov-r@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Abugova</surname><given-names>Y. G.</given-names></name><name xml:lang="ru"><surname>Абугова</surname><given-names>Ю. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dyakonova</surname><given-names>Y. Y.</given-names></name><name xml:lang="ru"><surname>Дьяконова</surname><given-names>Ю. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makarova</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Макарова</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Myakova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Мякова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Children’s Clinical Hospital&#13;
&#13;
Federal Research Center of Pediatric Hematology, Oncology and Immunology</institution></aff><aff><institution xml:lang="ru">Российская детская клиническая Российская больница&#13;
&#13;
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии&#13;
Минздравсоцразвития России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Children’s Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Российская детская клиническая Российская больница</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-02-24" publication-format="electronic"><day>24</day><month>02</month><year>2011</year></pub-date><volume>6</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>35</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2014-07-24"><day>24</day><month>07</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-07-24"><day>24</day><month>07</month><year>2014</year></date></history><permissions><copyright-year>2011</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/103">https://oncohematology.abvpress.ru/ongm/article/view/103</self-uri><abstract xml:lang="en"><p>Thyroid diseases, especially hypothyroidism, are among the most frequent endocrine complications in patients with Hodgkin lymphoma whohave received neck irradiation. Thyroid function was evaluated in 34 patients (11 males and 23 females) after combined chemo radiotherapyof Hodgkin lymphoma according to modified DAL-HD-90M and GPOH-HD-2002 protocols. The median age was 15.9 years (range 5–18 years), the median time from the end of therapy was 1.08 years (range 1 month–4.9 years). 33 patients received radiotherapy to the neck region: 12 children — 20 Gy, 9 — 25 Gy, 10 — 30 Gy, 2 — 35 Gy. These patients were investigated by clinical examination, thyroid ultrasound and thyroid function tests. Thyroid abnormalities were detected in 4 of 21 patients who received 20–25 Gy (1 case of autoimmune thyroiditis and 3 cases of subclinical hypothyroidism) and in 3 of 12 patients who received 30–35 Gy (2 cases of autoimmune thyroiditis and 1 case of subclinical hypothyroidism). Autoimmune thyroiditis also developed in patient who received only 35 Gy mediastinum irradiation. Age, sex, follow-up time, irradiation dose were not significant factors in the thyroid dysfunction development. Thyroid examination must be obligatory part of the follow-up examination of patients with Hodgkin lymphoma.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>children</kwd><kwd>adolescents</kwd><kwd>Hodgkin lymphoma</kwd><kwd>thyroid gland</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>подростки</kwd><kwd>лимфома Ходжкина</kwd><kwd>щитовидная железа</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Hoppe R.T., Mauch P.T., Armitage J.O. et al. Hodgkin Lymphoma. Lippincott Williams &amp; Wilkins. Philadelphia, 2007.</mixed-citation><mixed-citation xml:lang="ru">Hoppe R.T., Mauch P.T., Armitage J.O. et al. Hodgkin Lymphoma. Lippincott Williams &amp; Wilkins. Philadelphia, 2007.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Jereczek-Fossa B.A., Alterio D., Jassem J. et al. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004;30(4):369–84.</mixed-citation><mixed-citation xml:lang="ru">Jereczek-Fossa B.A., Alterio D., Jassem J. et al. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004;30(4):369–84.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Ильин Н.В., Виноградова Ю.Н. Поздние осложнения терапии больных лимфомой Ходжкина. Практич онкол 2007;8(2):96–101.</mixed-citation><mixed-citation xml:lang="ru">Ильин Н.В., Виноградова Ю.Н. Поздние осложнения терапии больных лимфомой Ходжкина. Практич онкол 2007;8(2):96–101.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Constine L.S., Donaldson S.S., McDougall I.R. et al. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 1984;53(4):878–83.</mixed-citation><mixed-citation xml:lang="ru">Constine L.S., Donaldson S.S., McDougall I.R. et al. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 1984;53(4):878–83.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Sklar C., Whitton J., Mertens A. et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227–32.</mixed-citation><mixed-citation xml:lang="ru">Sklar C., Whitton J., Mertens A. et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227–32.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Altman A.J. Supportive care of children with cancer. The Johns Hopkins University Press, Baltimore, 2004.</mixed-citation><mixed-citation xml:lang="ru">Altman A.J. Supportive care of children with cancer. The Johns Hopkins University Press, Baltimore, 2004.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Lanzkowsky P. Manual of Pediatric Hematology and Oncology. Elsevier academic press, 2005.</mixed-citation><mixed-citation xml:lang="ru">Lanzkowsky P. Manual of Pediatric Hematology and Oncology. Elsevier academic press, 2005.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Кияев А.В. Аутоиммунный тиреоидит у детей. Попробуем взглянуть поиному? Клинич и экспер тиреоидология 2008;4(3):23–7.</mixed-citation><mixed-citation xml:lang="ru">Кияев А.В. Аутоиммунный тиреоидит у детей. Попробуем взглянуть поиному? Клинич и экспер тиреоидология 2008;4(3):23–7.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Самочатова Е.В., Владимирская Е.Б., Жесткова Н.М. и др. Болезнь Ходжкина у детей. М.: Алтус, 1997.</mixed-citation><mixed-citation xml:lang="ru">Самочатова Е.В., Владимирская Е.Б., Жесткова Н.М. и др. Болезнь Ходжкина у детей. М.: Алтус, 1997.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Jaksic J., Dumic M., Filipovic B. et al. Thyroid disease in a school population with thyromegaly. Arch Dis Child 1994;70(2):103–6.</mixed-citation><mixed-citation xml:lang="ru">Jaksic J., Dumic M., Filipovic B. et al. Thyroid disease in a school population with thyromegaly. Arch Dis Child 1994;70(2):103–6.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Van Leeuwen F.E., Klokman W.J., Veer M.B. et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;18(3):487–97.</mixed-citation><mixed-citation xml:lang="ru">Van Leeuwen F.E., Klokman W.J., Veer M.B. et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;18(3):487–97.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Swerdlow A.J., Barber J.A., Hudson G.V. et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18(3):498–509.</mixed-citation><mixed-citation xml:lang="ru">Swerdlow A.J., Barber J.A., Hudson G.V. et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18(3):498–509.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
